Cargando…
Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review
Avoidance of immune destruction is recognized as one of the hallmarks of cancer development. Although first predicted as a potential antitumor treatment modality more than 50 years ago, the widespread clinical use of cancer immunotherapies has only recently become a reality. Cancer immunotherapy wor...
Autores principales: | Welty, Nathan E., Gill, Saar I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830230/ https://www.ncbi.nlm.nih.gov/pubmed/36636439 http://dx.doi.org/10.1016/j.jaccao.2022.11.006 |
Ejemplares similares
-
Cardiac Tumors: JACC CardioOncology State-of-the-Art Review
por: Tyebally, Sara, et al.
Publicado: (2020) -
Electrophysiological Manifestations of Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review
por: Hartnett, Jack, et al.
Publicado: (2021) -
Considerations of Competing Risks Analysis in Cardio-Oncology Studies: JACC: CardioOncology State-of-the-Art Review
por: Li, Yimei, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review
por: Tan, Sean, et al.
Publicado: (2022) -
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review
por: Suero-Abreu, Giselle Alexandra, et al.
Publicado: (2022)